



Fresenius Medical Care AG (FMS)

Updated February 26th, 2023 by Nathan Parsh

Key Metrics

Current Price:	\$20	5 Year CAGR Estimate:	0.5%	Market Cap:	\$12 B
Fair Value Price:	\$14	5 Year Growth Estimate:	3.0%	Ex-Dividend Date:	05/12/23 ¹
% Fair Value:	140%	5 Year Valuation Multiple Estimate:	-6.5%	Dividend Payment Date:	05/26/23 ²
Dividend Yield:	3.6%	5 Year Price Target	\$17	Years Of Dividend Growth:	24 ³
Dividend Risk Score:	B	Retirement Suitability Score:	B	Rating:	Sell

Overview & Current Events

Fresenius Medical Care AG is a diversified healthcare corporation focused on products and services related to renal (kidney) diseases. The company's services include kidney dialysis, clinical laboratory testing, and kidney diagnostic procedures. Fresenius Medical is headquartered in Germany. United States investors can initiate an ownership stake in Fresenius Medical through American Depository Receipts that trade on the New York Stock Exchange under the ticker FMS. Two ADR shares equals one share of the underlying company.

On February 22nd, 2023, Fresenius Medical announced fourth quarter and full year results for the period ending December 31st, 2022. In constant currency, quarterly revenue was up 2% while adjusted operating income fell 28% due to higher expenses. For the year, revenue improved 2% while net income decreased 37%.

Revenue for Care Delivery, formerly known as Health Care Services, grew 3% organically due to strong results in the EMEA and Asia-Pacific regions. North America was stable. Care Enablement, formerly known as Health Care Products, improved 0.2% as in-center disposables was offset by lower sales of machines for chronic treatments.

Fresenius Medical provided an outlook for 2023 as well, with the company expecting revenue to grow at a low to mid-single-digit percentage. Earnings-per-share are projected to be flat or decline by as much as a high single-digit percentage. We have initiated our forecast accordingly.

Growth on a Per-Share Basis

Year	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2028
EPS	\$1.83	\$1.73	\$1.69	\$2.03	\$2.08	\$2.46	\$2.43	\$2.70	\$1.97	\$1.21	\$1.10	\$1.28
DPS	\$0.48	\$0.53	\$0.43	\$0.43	\$0.53	\$0.55	\$0.45	\$0.72	\$0.82	\$0.71	\$0.71	\$0.82
Shares⁴	603	604	611	614	613	613	602	598	586	586	586	575

Although Fresenius Medical has lofty forward-looking growth targets, it has been unable to achieve strong growth historically, compounding its adjusted earnings-per-share at 0.2% per year over the last decade. We are now forecasting 3% annualized earnings-per-share growth over the next five years, down from 6% previously. We anticipate that the company will deliver earnings-per-share of \$1.10 in 2023. Applying a 3% growth rate to our 2023 earnings-per-share projection leads to 2028 earnings-per-share estimate of \$1.28.

Fresenius Medical Care has not prioritized growing its dividend payments in the past. However, the company has increased its dividend for 24 years in local currency. We forecast the dividend will grow in line with earnings-per-share.

¹ Estimated ex-dividend date

² Estimated dividend payment date

³ In local currency

⁴ In millions of shares

Disclosure: This analyst has no position in the security discussed in this research report, and no plans to initiate one in the next 72 hours.



Fresenius Medical Care AG (FMS)

Updated February 26th, 2023 by Nathan Parsh

Valuation Analysis

Year	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	Now	2028
Avg. P/E	18.5	20.1	24.3	21.1	18.5	13.2	16.7	16.6	16.5	26.8	18.2	13.0
Avg. Yld.	1.4%	1.5%	1.1%	1.0%	1.1%	1.3%	1.8%	1.8%	2.5%	2.2%	3.6%	5.0%

Shares of Fresenius Medical have increased by \$6, or 43%, since our October 31st, 2022 report. The stock has traded with an average price-to-earnings ratio of 19.2 over the last decade. We are reaffirming our 2028 target P/E of 13 from 16 to reflect the weakness in the company's business. For context, the company is trading at a price-to-earnings ratio of 18.2 today based off of earnings-per-share estimates for the current year. If the company's P/E ratio were to reach our target by 2028, then valuation would be 6.5% headwind to annual returns over this period of time.

Income investors should note that the German government imposes a 26.375% withholding tax on dividend payments made to international investors. This reduces Fresenius Medical's net dividend yield to ~2.7%.

Safety, Quality, Competitive Advantage, & Recession Resiliency


Year	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2028
Payout	26%	31%	25%	21%	26%	22%	19%	27%	42%	59%	65%	65%

A key competitive advantage for Fresenius Medical is its lineup of kidney dialysis and diagnostic products. The company is a global leader in the area of dialysis and has more facilities worldwide than any other company in this sector. Fresenius Medical serves as a one-stop shop for customers requiring dialysis related treatments. Fresenius Medical managed to increase earnings-per-share during the last recession. The company's products make it so that patients' can control their kidney failure, making it likely that the company will perform well recessions.

Final Thoughts & Recommendation

Following fourth quarter results, we expect Fresenius Medical to return 0.5% per year through 2028, down from 14.6% previously. Our projected return stems from a 3% earnings growth rate and a starting yield of 3.6%, that are nearly offset by a valuation headwind. The stock has enjoyed a massive rally since our previous report. As a result, we now view shares of the company as a sell due to projected returns.

Total Return Breakdown by Year



[Click here to rate and review this research report. Your feedback is important to us.](#)

Disclosure: This analyst has no position in the security discussed in this research report, and no plans to initiate one in the next 72 hours.



Fresenius Medical Care AG (FMS)

Updated February 26th, 2023 by Nathan Parsh

Income Statement Metrics

Year	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022
Revenue	14,051	17,314	17,150	18,339	20,140	19,539	19,565	20,396	20,846	20,457
Gross Profit	4,557	5,463	5,745	6,216	6,816	6,087	6,041	6,324	6,007	5,600
Gross Margin	32.4%	31.6%	33.5%	33.9%	33.8%	31.2%	30.9%	31.0%	28.8%	27.4%
SG&A Exp.	2,291	2,892	3,272	3,467	4,120	3,407	3,394	3,579	3,663	3,991
D&A Exp.	623	765	719	776	833	932	1,784	2,040	1,921	1,939
Operating Profit	2,145	2,438	2,331	2,586	2,570	2,545	2,458	2,524	2,083	1,368
Op. Margin	15.3%	14.1%	13.6%	14.1%	12.8%	13.0%	12.6%	12.4%	10.0%	6.7%
Net Profit	1,067	1,143	1,060	1,266	1,449	2,340	1,343	1,330	1,147	710
Net Margin	7.6%	6.6%	6.2%	6.9%	7.2%	12.0%	6.9%	6.5%	5.5%	3.5%
Free Cash Flow	1,238	1,017	1,007	1,108	1,413	1,186	1,614	3,633	1,935	1,522
Income Tax	569	638	627	692	502	603	450	572	417	343

Balance Sheet Metrics

Year	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022
Total Assets	23,120	25,381	25,365	26,961	28,823	30,019	36,893	38,976	38,911	38,343
Cash & Equivalents	683	634	549	749	1,173	2,454	1,129	1,330	1,678	1,366
Acc. Receivable	3,450	3,669	3,751	4,201	4,566	3,799	3,927	3,984	3,973	3,936
Inventories	1,097	1,116	1,341	1,414	1,549	1,678	1,863	2,331	2,307	2,462
Goodwill & Int.	12,416	13,952	13,863	14,545	15,341	14,746	17,299	17,637	17,913	18,563
Total Liabilities	13,635	15,353	14,869	15,279	15,832	15,260	22,076	23,809	23,083	21,775
Accounts Payable	667	714	781	888	885	909	936	1,018	971	999
Long-Term Debt	8,416	9,466	8,646	8,597	8,935	8,632	10,168	9,702	9,704	9,152
Total Equity	9,235	9,443	9,887	10,548	11,781	13,450	13,395	13,794	14,378	15,002
LTD/E Ratio	0.91	1.00	0.87	0.82	0.76	0.64	0.76	0.70	0.67	0.61

Profitability & Per Share Metrics

Year	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022
Return on Assets	4.7%	4.7%	4.2%	4.8%	5.2%	8.0%	4.0%	3.5%	2.9%	1.8%
Return on Equity	11.7%	12.2%	11.0%	12.4%	13.0%	18.6%	10.0%	9.8%	8.1%	4.8%
ROIC	6.0%	6.1%	5.5%	6.4%	6.9%	10.3%	5.6%	5.3%	4.6%	2.8%
Shares Out.	603	604	611	614	613	613	602	598	586	586
Revenue/Share	23.12	28.57	28.11	29.90	32.73	31.79	32.32	34.68	35.58	34.88
FCF/Share	2.04	1.68	1.65	1.81	2.30	1.93	2.67	6.18	3.30	2.60

Note: All figures in millions of U.S. Dollars unless per share or indicated otherwise.

Disclaimer

Nothing presented herein is, or is intended to constitute, specific investment advice. Nothing in this research report should be construed as a recommendation to follow any investment strategy or allocation. Any forward-looking statements or forecasts are based on assumptions and actual results are expected to vary from any such statements or forecasts. No reliance should be placed on any such statements or forecasts when making any investment decision. While Sure Dividend has used reasonable efforts to obtain information from reliable sources, we make no representations or warranties as to the accuracy, reliability or completeness of third-party information presented herein. No guarantee of investment performance is being provided and no inference to the contrary should be made. There is a risk of loss from an investment in marketable securities. Past performance is not a guarantee of future performance.